Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Adverse Events | NCT01419197 | There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood. | Contradiction | [
13,
17
] | [] | {'Clinical Trial ID': 'NCT01419197', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatmen... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6173faf3-f845-4cf1-94a9-756d1bff48bb | |
Single | Intervention | NCT02006979 | Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02006979', 'Intervention': ['INTERVENTION 1: ', ' Exercise', ' an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise', 'INTERVENTION 2: ', ' Usual Care', ' no exercise for 72 hours prior or 48 hours post each cycle of ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 512c72ab-f1b3-450d-8167-6e0d8d2bf5dd | |
Single | Results | NCT00849472 | More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00849472', 'Intervention': ['INTERVENTION 1: ', ' AC, Followed by Weekly Paclitaxel and Concurrent Pazopanib', ' Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104 | |
Single | Results | NCT00548184 | 64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00548184', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib + Trastuzumab', ' All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week'], 'Eligibility': ['Inclusion Criteria:', ' All patients must be female.', ' Signed informed con... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 87987ebb-6799-4d1d-8529-d33c6b7799f8 | |
Comparison | Eligibility | NCT00097721 | NCT00896649 | Black women cannot take part in the secondary trial or the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] | [
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00097721', 'Intervention': ['INTERVENTION 1: ', ' E7389 28 Day Schedule', ' E7389 1.4 mg/m^2 intravenous bolus on Days 1, 8 and 15 of a 28 day cycle.', 'INTERVENTION 2: ', ' E7389 21 Day Schedule', ' E7389 1.4 mg/m^2 intravenous bolus on Days 1 and 8 of a 21 day cycle.'], 'Eligibility': ['... | {'Clinical Trial ID': 'NCT00896649', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Positron Emission Mammography and Questionnaire', ' questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patien... | bf94f208-a29b-4d8f-92a7-3cb8241ce344 |
Single | Eligibility | NCT02988986 | Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial. | Contradiction | [
0,
20
] | [] | {'Clinical Trial ID': 'NCT02988986', 'Intervention': ['INTERVENTION 1: ', ' TAK-228 Plus Tamoxifen', ' TAK-228 will be orally administered at 30 mg weekly for 16 weeks.', ' Tamoxifen will be orally administered at 20 mg daily for 16 weeks.', ' TAK-228: MTORC1/2 inhibitor', ' Tamoxifen: Non-steroidal anti-estrogen'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c68f6822-24fa-44b5-bf63-c272a8031fab | |
Comparison | Adverse Events | NCT02019277 | NCT00863655 | the primary trial and the secondary trial recorded none of the same types of adverse events | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT02019277', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Pertuzumab, and Taxane', " Participants received first-line therapy with pertuzumab administered via IV infusion on Day 1 of first treatment cycle (1 cycle = 21 days) at a loading dose of 840 mg, followed by 420 mg on Day 1 of ea... | {'Clinical Trial ID': 'NCT00863655', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Exemestane', ' Everolimus 10 mg daily in combination with exemestane 25 mg daily', 'INTERVENTION 2: ', ' Placebo + Exemestane', ' Placebo of everolimus in combination with exemestane 25 mg daily'], 'Eligibility': ['Inclusion Cr... | 54a459cf-f01a-4abc-a8cf-0efebc01c694 |
Single | Eligibility | NCT02683083 | sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial. | Contradiction | [
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT02683083', 'Intervention': ['INTERVENTION 1: ', ' [131I]-SGMIB Anti-HER2 VHH1', ' All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).'], 'Eligibility': ['Inclusion Criteria:', ' Subjects will only be included in the st... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dd4b5a08-c033-4429-81d0-1ad59596edbd | |
Comparison | Intervention | NCT01153672 | NCT01432145 | Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01153672', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)', ' Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 wee... | {'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given c... | d97ebc59-ab4b-462a-9057-12f4fc46df56 |
Comparison | Intervention | NCT01727011 | NCT01420146 | the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01727011', 'Intervention': ['INTERVENTION 1: ', ' IPAS', ' Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelera... | {'Clinical Trial ID': 'NCT01420146', 'Intervention': ['INTERVENTION 1: ', ' Zr89-trastuzumab PET/CT', ' Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm'], 'Eligibility': ['Inclusion criteria:', ' All patients selected for this imaging study are patients scheduled to start trastuzumab-... | 2e4c7d0b-f1a2-4204-bac3-7445852fd916 |
Comparison | Intervention | NCT01928186 | NCT00684983 | All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of the secondary trial receive all of these. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01928186', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (FLT PET)', ' Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.'... | {'Clinical Trial ID': 'NCT00684983', 'Intervention': ['INTERVENTION 1: ', ' Arm A', ' Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Gi... | fafac1e0-1eaa-4a99-8f3f-72b3f71c4691 |
Single | Adverse Events | NCT01989676 | the primary trial only records cardiovasuclar adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01989676', 'Intervention': ['INTERVENTION 1: ', ' PF-05280014', ' Participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer received PF-05280014 on Days 1, 8, 15 and 22 of each 28-day cycle followed by paclitaxel on Days 1, 8 and 15 of each 28-day cycle both as... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4546c169-cc5c-4e03-bcce-31d491ed18e0 | |
Single | Eligibility | NCT00612560 | children and illiterate adults are not able to take part in the primary trial. | Entailment | [
0,
1,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00612560', 'Intervention': ['INTERVENTION 1: ', ' Arm A - Flaxseed & Active Anastrazole', ' 25 mg flaxseed per day and 1 mg anastrozole pill per day', ' Anastrozole: 1 mg per day', ' flaxseed: 25 g per day ground', 'INTERVENTION 2: ', ' Arm B - Flaxseed', ' Flaxseed 25 mg per day and 1 p... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1bb3badf-41c6-4741-90f0-367473ce254d | |
Comparison | Eligibility | NCT02806544 | NCT00605267 | A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial. | Contradiction | [
0,
5,
6
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02806544', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg by mouth daily', ' Tamoxifen: Tamoxifen 20mg by mouth daily'], 'Eligibility': ['Inclusion Criteria:', ' Patient evaluated and treated at INCAN', ' Patients must provide informed consent', ' Patient must be 18... | {'Clinical Trial ID': 'NCT00605267', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole (investigational product) 1mg tablet given once a day orally and goserelin acetate 3.6 mg/ month depot injection', 'INTERVENTION 2: ', ' Tamoxifen 20 mg', ' Tamoxifen (comparator) 20mg tablet given once a da... | 87953ba3-3e94-421c-b426-b716562b8b5d |
Comparison | Intervention | NCT00686127 | NCT01129622 | dosages are specified in the intervention section of the secondary trial and the primary trial | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00686127', 'Intervention': ['INTERVENTION 1: ', ' Lidocaine Patch', ' Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day.', 'INTERVENTION 2: ', ' Placebo Patch', ' Placebo patch: 1 patch was applied topical... | {'Clinical Trial ID': 'NCT01129622', 'Intervention': ['INTERVENTION 1: ', ' Letrozole, Breast Enhancement, Safety', ' Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment). Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI.'], 'Eligibili... | 847b4dbe-428f-431c-8916-2a9c0c80cce4 |
Single | Adverse Events | NCT00232505 | There were no instances of patients with abnormal heart rates in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00232505', 'Intervention': ['INTERVENTION 1: ', ' Cetuximab', ' Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.', ' c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9c00b318-0a3a-43c9-a6cd-2983c07be393 | |
Comparison | Intervention | NCT02597452 | NCT01929395 | the primary trial and the secondary trial do not use cyclical interventions. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02597452', 'Intervention': ['INTERVENTION 1: ', ' Intelligent Breast Exam, iBE', ' Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for partic... | {'Clinical Trial ID': 'NCT01929395', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Addition of Supine MRI to Conventional Imaging', ' Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)'], 'Eligibility': ['Inclusion Criteria Phase 1', ' Age greater than/equal to 18 years', ' His... | cbfe14a5-5169-4de3-b69f-13b489be949a |
Single | Results | NCT00325598 | There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00325598', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 (36 Gy)', ' 36 Gy in 9 fractions BID x 4 1/2 treatment days', ' Partial Breast Irradiation (PBI)', 'INTERVENTION 2: ', ' Cohort 2 (40 Gy)', ' 40 Gy in 10 fractions BID over 5 treatment days', ' Partial Breast Irradiation (PBI)'],... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bd6bf811-e9a8-4e1e-ace1-703aa8f5374b | |
Comparison | Adverse Events | NCT01332630 | NCT00121134 | There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01332630', 'Intervention': ['INTERVENTION 1: ', ' TPI 287', ' TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prio... | {'Clinical Trial ID': 'NCT00121134', 'Intervention': ['INTERVENTION 1: ', ' Group A- Bevacizumab Alone', ' Bevacizumab 15 mg/kg every 3 wks for 1 year', 'INTERVENTION 2: ', ' Group B-Bevacizumab+Cyclophosphamide+Methotrexate', ' Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for ... | 3c4d9ab0-5e16-48b3-96d4-ae9d337b2822 |
Comparison | Eligibility | NCT02073487 | NCT03371732 | Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT02073487', 'Intervention': ['INTERVENTION 1: ', ' T-DM1 + Lapatinib + Abraxane', ' T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.', ' T-DM1: antibody-drug conjugate of trastuzumab and emtansine', ' Lapatinib: Dua... | {'Clinical Trial ID': 'NCT03371732', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Arm 1: Motivational Intervention group', ' Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single ... | eae76b80-107c-4469-b06f-73d5f7a4c1d5 |
Single | Results | NCT00347919 | less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00347919', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg', ' Lapatinib 1500 milligrams (mg) administered orally once a day', 'INTERVENTION 2: ', ' Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg', ' Lapatinib 1000 mg and Pazopanib 400 mg administered orally once a day'], ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6cf7d10e-902e-4f78-85f6-e06d63e1cd0e | |
Single | Eligibility | NCT00334542 | A Female patients with a bilateral mastectomy would be excluded from the primary trial. | Entailment | [
6
] | [] | {'Clinical Trial ID': 'NCT00334542', 'Intervention': ['INTERVENTION 1: ', ' Simvastatin', ' Simvastatin 40 mg for 24-28 weeks'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:', ' Ductal carcinoma in situ', ' Stage I-III... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 91ad45ae-6714-4c27-ac1a-d8ff8e89684f | |
Single | Eligibility | NCT00605267 | Only men can be eligible for the primary trial. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00605267', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole (investigational product) 1mg tablet given once a day orally and goserelin acetate 3.6 mg/ month depot injection', 'INTERVENTION 2: ', ' Tamoxifen 20 mg', ' Tamoxifen (comparator) 20mg tablet given once a da... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 91cf53f9-7233-49ee-a619-c027f6db67ac | |
Single | Adverse Events | NCT02273973 | Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea. | Entailment | [
0,
11,
12
] | [] | {'Clinical Trial ID': 'NCT02273973', 'Intervention': ['INTERVENTION 1: ', ' Experimental: Taselisib + Letrozole', ' Participants received 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 wee... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 78894316-fc7d-4d61-a2d4-9ea369bfce20 | |
Single | Adverse Events | NCT00879086 | Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2. | Entailment | [
0,
3,
4,
5,
14,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00879086', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cy... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 889e6622-1614-4f6c-a47c-e7caad6e154f | |
Comparison | Eligibility | NCT01740323 | NCT00127205 | the secondary trial and the primary trial accept patients in the same age range. | Entailment | [
0,
1
] | [
15,
16,
17
] | {'Clinical Trial ID': 'NCT01740323', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Placebo', ' Placebo: daily placebo for 6 weeks', 'INTERVENTION 2: ', ' Curcumin', ' 500 mg BID', ' Curcumin: 500 mg BID'], 'Eligibility': ['Inclusion Criteria:', ' Female breast cancer patients over the age of 18 will be recr... | {'Clinical Trial ID': 'NCT00127205', 'Intervention': ['INTERVENTION 1: ', ' Arm I Zoledronate', ' Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.', ' zoledronic acid: Given IV', 'INTERVENTION 2: ', ' Arm II Clodronate', ' Patients receive oral c... | 4577d986-d7e5-4b5d-9852-b944a6f7f252 |
Comparison | Results | NCT02472964 | NCT00089661 | the primary trial studies tumours response, whereas the secondary trial investigates changes in Bone Mineral Density. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02472964', 'Intervention': ['INTERVENTION 1: ', ' Herceptin© + Taxane', ' Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint... | {'Clinical Trial ID': 'NCT00089661', 'Intervention': ['INTERVENTION 1: ', ' Denosumab 60 mg Q6M', '[Not Specified]', 'INTERVENTION 2: ', ' Placebo', '[Not Specified]'], 'Eligibility': ['Histologically or cytologically confirmed adenocarcinoma of the breast', ' Subjects with early stage disease who are estrogen recep... | e83b56ba-d129-4cde-976d-2865e67ef4a3 |
Single | Adverse Events | NCT01705691 | The majority of patients in the primary trial suffered from Kidney stones. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01705691', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Paclitaxel Then AC', ' Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles', ' Paclitaxel: 80 mg/m2 IV over 60 minutes weekly for 12 weeks', ' Doxorubicin: 60 mg/m2 IV... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | eee75423-9a61-4a57-8baf-8f91b9562486 | |
Comparison | Results | NCT00802945 | NCT01231659 | Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00802945', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102 14 Day', ' NKTR-102: NKTR-102 given on a q14 day schedule', 'INTERVENTION 2: ', ' NKTR-102 21 Days', ' NKTR-102: NKTR-102 given on a q21 day schedule'], 'Eligibility': ['Inclusion Criteria:', ' Inoperable metastatic or locally adv... | {'Clinical Trial ID': 'NCT01231659', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Letrozole', ' All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.'], 'Eligibility': ['Inclusion Criteria:'... | 9e046221-7d4b-4681-a374-96793350927d |
Comparison | Intervention | NCT01738438 | NCT00331552 | Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01738438', 'Intervention': ['INTERVENTION 1: ', ' Cabozantinib', ' Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically ... | {'Clinical Trial ID': 'NCT00331552', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Cyclophosphamide, Doxil, Trastuzumab', ' Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease p... | 5448c6b8-244c-4a42-bbef-e1a1a2e254e2 |
Comparison | Eligibility | NCT00429572 | NCT02455453 | pre-menopausal patients are excluded from the secondary trial, but eligible for the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00429572', 'Intervention': ['INTERVENTION 1: ', ' Allogeneic Transplantation', ' Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.'], 'Eligibility': ['Inclusion Criteria:', ' Recurrent or residual me... | {'Clinical Trial ID': 'NCT02455453', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic FFNP-PET/CT Scan', ' (2) 18F-FFNP-PET/CT scans', ' First one prior to estradiol challenge test', ' Second one immediately following one day of estradiol challenge test', ' (1) FDG-PET/CT scan at screening', ' The estradiol chal... | 135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2 |
Comparison | Eligibility | NCT01506609 | NCT00656019 | Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial, but are eligible for the primary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | {'Clinical Trial ID': 'NCT01506609', 'Intervention': ['INTERVENTION 1: ', ' Group 2 Placebo + Carboplatin/Paclitaxel', ' Placebo BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.', 'INTERVENTION 2: ', ' ... | {'Clinical Trial ID': 'NCT00656019', 'Intervention': ['INTERVENTION 1: ', ' Normal Vitamin D Levels', ' No additional Vitamin D administered', 'INTERVENTION 2: ', ' Low-normal Vitamin D Levels', ' 2000 IU dose of Vitamin D per day administered orally'], 'Eligibility': ['INCLUSION CRITERIA:', ' Undergoing core need... | 8d450d42-4eb1-4edb-be76-b2885964aa90 |
Single | Intervention | NCT01104584 | the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01104584', 'Intervention': ['INTERVENTION 1: ', ' CMRM Versus UMRM', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2674e194-3113-4a11-b2cc-f089d960d194 | |
Single | Adverse Events | NCT00490646 | Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00490646', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV', ' trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptabl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a7232387-b266-4bfb-8df8-ca9789188500 | |
Single | Results | NCT01959490 | In total only one participant of the primary trial did not achieve Pathological Complete Response. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01959490', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1P (HER2 Positive)', ' Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2e317381-2704-4d06-a793-1d2b29139969 | |
Single | Intervention | NCT00559507 | the primary trial participants are given saracatinib PO every single day of the study duration. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00559507', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy)', ' Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 030316a2-fb48-469d-9c55-04cdc9a37fb6 | |
Single | Results | NCT00338286 | No participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00338286', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care (SOC)', " Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.", 'INTERVENTION 2: ', ' Epoetin Alfa', ' Participants received SOC plus epoetin alfa 40,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2c723e02-14d8-4a80-a95f-517e904bbbad | |
Comparison | Adverse Events | NCT00885755 | NCT01075100 | Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT00885755', 'Intervention': ['INTERVENTION 1: ', ' Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks)', ' This group included participants who progressed after at least six weeks of trastuzumab/taxane treatment. In Part 1 of the study, participants received standard first-line therapy with t... | {'Clinical Trial ID': 'NCT01075100', 'Intervention': ['INTERVENTION 1: ', ' Triple Negative', ' ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.', 'INTERVENTION 2: ', ' HR Positive', ' ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/H... | 8befa03f-c3da-4950-8d27-491ea06b51ed |
Single | Results | NCT01307891 | Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01307891', 'Intervention': ['INTERVENTION 1: ', ' Abraxane + Tigatuzumab', ' Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every oth... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 32424458-a3e2-440a-9693-6a2f8d4aaddb | |
Single | Adverse Events | NCT00468585 | the primary trial did not record any skin infections in their patients. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00468585', 'Intervention': ['INTERVENTION 1: ', ' Group 0', ' Capecitabine - AM 1500mg; PM 1500 mg; total daily 3000 mg', 'INTERVENTION 2: ', ' Group 1', ' Capecitabine - AM 1500 mg; PM 2000 mg; total daily 3500 mg'], 'Eligibility': ['Inclusion Criteria:', ' Patient (male or female) with ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a2b25229-c003-49c3-8b0b-94b68f756d3c | |
Comparison | Intervention | NCT00852930 | NCT02308020 | Laser Therapy is only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00852930', 'Intervention': ['INTERVENTION 1: ', ' Laser Therapy Alone', ' therapist administered laser treatment', ' laser: therapist administered laser', 'INTERVENTION 2: ', ' Mld Alone', ' therapist administered manual lymphatic drainage', ' manual lymphatic drainage: therapist adminis... | {'Clinical Trial ID': 'NCT02308020', 'Intervention': ['INTERVENTION 1: ', ' Part A Abemaciclib: HR+, HER2+ Breast Cancer', ' Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants wit... | 728721c4-6376-4ab8-9e4a-af8596bd1ab3 |
Comparison | Adverse Events | NCT01086605 | NCT00570921 | the primary trial and the secondary trial both record cases of Cholecystitis. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT01086605', 'Intervention': ['INTERVENTION 1: ', ' Arm I/Group A (Pixantrone IV Day 1)', ' Patients receive 180 mg/m^2 pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', 'INTERVEN... | {'Clinical Trial ID': 'NCT00570921', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Everolimus', ' Fulvestrant + Everolimus', ' Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day ... | c7151ad6-bcac-48e1-ba1e-e6f56a043804 |
Single | Adverse Events | NCT02015676 | There is 1 case (1.45%) of thrombocytopenia in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT02015676', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Doxorubicin, Paclitaxel; Phase II', ' Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours on Day 1 (Week 1), followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or un... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4f71e33c-4f0f-4952-bb03-52402be5f9f4 | |
Single | Eligibility | NCT03004534 | Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial. | Contradiction | [
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT03004534', 'Intervention': ['INTERVENTION 1: ', ' Presurgical Molecular Assessment', ' Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.', ' darolutamide: Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.'], 'Eligibil... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ef675459-a7d9-4ea1-8963-c95682c38d15 | |
Comparison | Eligibility | NCT02658734 | NCT02073487 | Female Patients with LVEF > 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] | {'Clinical Trial ID': 'NCT02658734', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Prospect... | {'Clinical Trial ID': 'NCT02073487', 'Intervention': ['INTERVENTION 1: ', ' T-DM1 + Lapatinib + Abraxane', ' T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.', ' T-DM1: antibody-drug conjugate of trastuzumab and emtansine', ' Lapatinib: Dua... | f9df9e45-eb68-4257-801e-b086a89374b8 |
Single | Results | NCT00319254 | the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00319254', 'Intervention': ['INTERVENTION 1: ', ' Bosutinib', ' Four bosutinib 100 milligram (mg) capsules, equivalent to 400 mg bosutinib orally once daily for 48 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent occurred.'], 'Eligibility': ['Inclusion Crit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94fc10ff-65e1-4b0a-8ff3-1cc48db3433e | |
Single | Results | NCT00820170 | According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00820170', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib and Paclitaxel', ' The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly p... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 958721dc-e374-4fd1-abb9-071add70bde3 | |
Single | Adverse Events | NCT01764022 | Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia. | Entailment | [
10,
13
] | [] | {'Clinical Trial ID': 'NCT01764022', 'Intervention': ['INTERVENTION 1: ', ' BCD-022 (CJSC BIOCAD)', ' BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BC... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19c0b2c7-e45c-4740-b25d-f6e738b59893 | |
Comparison | Adverse Events | NCT02896855 | NCT00171314 | the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT02896855', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Placebo + Trastuzumab + Docetaxel', ' Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg... | {'Clinical Trial ID': 'NCT00171314', 'Intervention': ['INTERVENTION 1: ', ' Upfront Zoledronic Acid', ' Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.', 'INTERVENTION 2: ', ' De... | 7bcfca9e-1b09-45d4-8165-cb6ac96b8815 |
Single | Adverse Events | NCT01095003 | Less than 5 patients in the primary trial experienced Earache. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01095003', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine Plus Capecitabine', ' Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks', ' Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e3a8be03-20e4-460d-9ebc-f958a515ac45 | |
Single | Results | NCT01118624 | Less than 5% of the primary trial participants achieved CR or PR. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01118624', 'Intervention': ['INTERVENTION 1: ', ' Pralatrexate', ' Study drug 190 mg/m^2 for 2 to 4 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 negative advanced or metastatic breast cancer', ' Disease has become worse after at least 1 prior chemotherapy regimen for advanced o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f1096271-3160-4483-9246-ba0d96735efb | |
Single | Results | NCT00004888 | More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00004888', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Doxorubicin and Taxotere', ' Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV, one hour after PLD completion, every 3 weeks for a total of 8 cycles. Dexamthasone 8 mg orally twice a day was administered the day bef... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 329b6871-2edc-4142-a4af-e7f8cef118ee | |
Comparison | Eligibility | NCT00365417 | NCT00853996 | To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2.5 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL. | Contradiction | [
11,
13,
14,
9,
10
] | [
17,
18,
20,
23
] | {'Clinical Trial ID': 'NCT00365417', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Study Treatment', ' Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine'], 'Eligibility': ['Inclusion Criteria:', ' Patients must be female.', ' The patient must be greater than/equal to 18 year... | {'Clinical Trial ID': 'NCT00853996', 'Intervention': ['INTERVENTION 1: ', ' Prevention (Acolbifene Hydrochloride)', ' Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.', ' acolbifene hydrochloride: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' ... | 67522762-9423-4e3d-bf75-247f84ba7f05 |
Single | Adverse Events | NCT02630693 | A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT02630693', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib (100mg)', ' Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules', ' Palbociclib 100mg: 100mg PO daily', ' Fulvestrant or Tamoxifen or Aromatase Inhibitor: given... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | efd37946-54f3-4813-b63d-6d7df6123677 | |
Single | Results | NCT02162667 | The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT02162667', 'Intervention': ['INTERVENTION 1: ', ' CT-P6', ' Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cyc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dcf62f43-04b7-4acb-b444-2d805238a8b1 | |
Comparison | Intervention | NCT03252145 | NCT00904033 | None of the subjects in the primary trial are required to injest any pills, and half the subjects in the secondary trial must take a weekly tablet. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT03252145', 'Intervention': ['INTERVENTION 1: ', ' Manual Lymph Drainage', ' Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb vol... | {'Clinical Trial ID': 'NCT00904033', 'Intervention': ['INTERVENTION 1: ', ' No Exercise', ' Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week', 'INTERVENTION 2: ', ' Exercise', ' Exercise Arm: Exercise consisting of progressive walking and resistance band training', ' Calcitriol+ Exercise Arm: ... | 83dc7b9a-b863-4f81-88fb-763afc3b79e8 |
Single | Adverse Events | NCT00075764 | The most common adverse event in cohort 1 of the primary trial is Neutropenia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00075764', 'Intervention': ['INTERVENTION 1: ', ' Arm I Anastrozole', ' Patients receive oral anastrozole once daily on days 1-28.', ' anastrozole: Given orally', 'INTERVENTION 2: ', ' Arm II Anastrozole and Fulvestrant', ' Patients receive oral anastrozole as in arm I. Patients also rece... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d446920a-2b8e-4452-b9f2-17d2771dbb07 | |
Comparison | Adverse Events | NCT01269346 | NCT01597193 | Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT01269346', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate in Combination With Trastuzumab', ' Eribulin Mesylate: Eribulin mesylate 1.4 mg/m^2 was administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.', ' Trastuzumab 8 mg/kg was ad... | {'Clinical Trial ID': 'NCT01597193', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation: Enzalutamide 80 mg', ' Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including a... | aa710138-bf2a-4a7f-8014-4513fa1f448b |
Comparison | Eligibility | NCT01340300 | NCT00671918 | Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial. | Entailment | [
0,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT01340300', 'Intervention': ['INTERVENTION 1: ', ' Exercise Training With Metformin', ' Exercise training with exercise physiologist with oral metformin', ' Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID', 'INTERVENTION 2:... | {'Clinical Trial ID': 'NCT00671918', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | aa38a1cc-35d6-4194-9e9e-3bcc0298a95c |
Single | Adverse Events | NCT01491737 | There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure. | Entailment | [
0,
2,
5
] | [] | {'Clinical Trial ID': 'NCT01491737', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy', ' Participants received pertuzumab at a loading dose of 840 mg followed by 420 mg along with trastuzumab at a loading dose of 8 mg/kg of body weight followed by 6 mg/kg of body weight on... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6a71c114-2e38-4d57-8f8b-8252d9c62cbe | |
Single | Intervention | NCT00407888 | Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00407888', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4333aaa3-dbe4-4275-a982-881fe25c96c0 | |
Single | Adverse Events | NCT00357110 | Only 6 patients in cohort 1 of the primary trial had Varicose Veins. | Contradiction | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00357110', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Anastrozole', ' fulvestrant 500 mg + anastrozole 1 mg', 'INTERVENTION 2: ', ' Anastrozole', 'anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with hormone receptor-positive early breast cancer ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d605b820-2915-4b19-b9cd-ca7850645f83 | |
Single | Eligibility | NCT01525589 | People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial. | Entailment | [
0,
13
] | [] | {'Clinical Trial ID': 'NCT01525589', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (BRCA+)', ' Patients with known deleterious BRCA1/2 mutation status at study entry', 'INTERVENTION 2: ', ' Cohort A1 (BRCA+/PARPi)', ' Patients with known deleterious BRCA1/2 mutation status and prior treatment with PARPi.'], 'Elig... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d6de70df-d113-4bc8-9d3b-b71f31937ebe | |
Comparison | Intervention | NCT03346161 | NCT01000662 | Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions, they are only testing effectiveness of consultations. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT03346161', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: BREASTChoice (Decision Tool)', " Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, ... | {'Clinical Trial ID': 'NCT01000662', 'Intervention': ['INTERVENTION 1: ', ' ARM 1 Daily Boost', ' Radiation Therapy', ' Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose... | 9f897b29-7cfa-414c-8cf6-212a68ec2216 |
Single | Results | NCT00676663 | The the primary trial placebo group performed much better than the test group, as a lower PFS is ideal. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00676663', 'Intervention': ['INTERVENTION 1: ', ' Exemestane 25 mg + Placebo', ' Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0d0deba5-c7bd-489b-a49d-c6af9a5cd92a | |
Single | Adverse Events | NCT00024102 | A patient in cohort 2 of the primary trial received a Plasma transfusion. | Contradiction | [
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00024102', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy', ' Patient/Physician choice of:', ' CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 by IV days 1 and 8) + 5-FU (600 mg/m^2 by IV days 1 and 8) repeated every 28 days for 6 cycles OR', ' AC: Cycloph... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4606f64f-64cc-4d73-a8be-75701c97008d | |
Single | Eligibility | NCT00478257 | Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. However, being pregnant is required. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00478257', 'Intervention': ['INTERVENTION 1: ', ' Effect of Bright Light', ' Effect of bright light on fatigue in women with breast cancer', 'INTERVENTION 2: ', ' Effect of Red Light', ' effect of red light on fatigue in women with breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 40bef815-18ed-4db5-8108-9a1cdbdd0a13 | |
Single | Results | NCT00319254 | the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00319254', 'Intervention': ['INTERVENTION 1: ', ' Bosutinib', ' Four bosutinib 100 milligram (mg) capsules, equivalent to 400 mg bosutinib orally once daily for 48 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent occurred.'], 'Eligibility': ['Inclusion Crit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5c676007-9ea4-4f80-82dd-89293237cb07 | |
Comparison | Eligibility | NCT01325428 | NCT00073073 | the secondary trial and the primary trial do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT01325428', 'Intervention': ['INTERVENTION 1: ', ' Part A: Afatinib Once Daily (OD).', ' Part A: Patients received Afatinib tablets, 40 mg taken orally Once Daily (OD) until PD. In case of treatment-related AEs, the 40 mg dose could be reduced by increments of 10 mg to 30 mg once daily or 20 ... | {'Clinical Trial ID': 'NCT00073073', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended... | a6682883-ace7-4d83-a35c-956928fdc75a |
Comparison | Adverse Events | NCT00265759 | NCT00866905 | 2 cases of hematolysis were recorded in the primary trial, none in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00265759', 'Intervention': ['INTERVENTION 1: ', ' Cohort A Arm I: Exemestane', ' Patients receive oral exemestane 25 mg once daily for up to 16-18 weeks prior to partial or radical mastectomy or lumpectomy with or without lymph node dissection', 'INTERVENTION 2: ', ' Cohort A Arm II: Letroz... | {'Clinical Trial ID': 'NCT00866905', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone/Cyclophosphamide', ' Systemic Therapy followed by surgery and possible radiation therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years.', ' Histologically confirmed invasive adenocarcinoma of the brea... | 1a271e29-477b-4819-a472-5c7c7df99e70 |
Single | Adverse Events | NCT01926886 | There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01926886', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 060e833e-384f-48f0-8e56-ebd95f55f221 | |
Single | Adverse Events | NCT01166763 | the primary trial only recorded three types of adverse events. | Entailment | [
0,
1,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT01166763', 'Intervention': ['INTERVENTION 1: ', ' High Dose Vitamin D3 (10,000 IU Weekly)', ' Group/Cohort Label vitamin D3', ' vitamin D3: oral capsules, 10,000 IU per week for 6 months'], 'Eligibility': ['Inclusion Criteria:', ' Subjects must be premenopausal women age 55 or younger, and... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ac193d32-156e-48bf-bc6b-d613691f869c | |
Single | Eligibility | NCT00503750 | All participants of the primary trial must have recently undergone either an echocardiography. | Contradiction | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00503750', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab and Abraxane Followed Trastuzumab and Vinorelbine', ' Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d79173da-5e59-4150-99bd-f1c20118dddc | |
Comparison | Eligibility | NCT01176916 | NCT00186121 | postmenopausal women are eligible for the primary trial, and Premenopausal women are eligible for the secondary trial. | Entailment | [
0,
3
] | [
0,
2
] | {'Clinical Trial ID': 'NCT01176916', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant ho... | {'Clinical Trial ID': 'NCT00186121', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole + Goserelin', ' Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily.'], 'Eligibility': ['INCLUSION CRITERIA'... | 50559f15-636d-4265-8f8c-4aad016c6c50 |
Single | Eligibility | NCT00635050 | Patients with Breast cancers that have estrogen receptors are included in the primary trial. | Contradiction | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00635050', 'Intervention': ['INTERVENTION 1: ', ' Doxil, Paclitaxel, Cyclophosphamide + Avastin', ' Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil, paclitaxel and cyclophosphamide with concurrent Avastin... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a5af6d2b-4cea-40aa-acdc-59fab5362b3e | |
Single | Intervention | NCT00941330 | Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00941330', 'Intervention': ['INTERVENTION 1: ', ' A: Exemestane', ' ARM A: Patients will be treated with exemestane.', ' Exemestane: 25 mg daily by mouth for 6 to 12 months.', 'INTERVENTION 2: ', ' B: Docetaxel and Cytoxan', ' ARM B: Patients will be treated with docetaxel and cytoxan.', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7e89b190-b8f7-4281-b0f1-0e65dcebf402 | |
Single | Adverse Events | NCT01565083 | There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial. | Contradiction | [
12,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01565083', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion', ' Pertuzumab IV infusion at a loading dose of 840 mg on Day 1 of Cycle 1 (cycle length = 21 days), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab IV infusion at a ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6036d341-9c6a-49fc-a2f4-19c0e2399f4c | |
Single | Eligibility | NCT01790932 | patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial, if this treatment ended over 5 years prior. | Contradiction | [
5,
6
] | [] | {'Clinical Trial ID': 'NCT01790932', 'Intervention': ['INTERVENTION 1: ', ' BKM120', ' BKM120: 100 mg capsule once daily each day of a 28 day cycle .', ' Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons.'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a84afa25-2741-4a08-9e6c-4049f5feca48 | |
Comparison | Intervention | NCT01669343 | NCT00146172 | the primary trial and the secondary trial do not have the same duration of intervention administration. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01669343', 'Intervention': ['INTERVENTION 1: ', ' Post-menopausal Women Using Adjuvant Letrozole', ' Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants', ' Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of... | {'Clinical Trial ID': 'NCT00146172', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 40 mg', 'Neratinb 40 mg qd', 'INTERVENTION 2: ', ' Neratinib 80 mg', 'Neratinib 80 mg qd'], 'Eligibility': ['Inclusion Criteria:', ' Her2/neu or Her1/EGFR positive cancer', ' Eastern Cooperative Oncology Group (ECOG) performance s... | 09e4c746-642a-4a5d-a267-25258a3f2ec0 |
Single | Adverse Events | NCT02502864 | the primary trial recorded the same number of occurences for every type of adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT02502864', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care + Surveys', ' Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys.'], 'Eligibility': ['Inclusion Criteria:', ' Must have histologi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 99855d11-e2e4-4a0e-b40e-2264ff128ac5 | |
Comparison | Intervention | NCT00712985 | NCT02038010 | Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00712985', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid 5 mg IV', ' Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).'], 'Eligibility': ['Inclusion ... | {'Clinical Trial ID': 'NCT02038010', 'Intervention': ['INTERVENTION 1: ', ' Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1)', ' Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of dis... | 54fe69c7-5a67-49b1-8bc5-c975133e2bb7 |
Single | Results | NCT00436566 | Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00436566', 'Intervention': ['INTERVENTION 1: ', ' AC/PTL', ' Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 76362fd3-3a07-4aa3-a072-b9075d2ea791 | |
Comparison | Adverse Events | NCT00878709 | NCT02447003 | the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | {'Clinical Trial ID': 'NCT00878709', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxici... | {'Clinical Trial ID': 'NCT02447003', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Pembrolizumab', ' Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants were administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle ... | 064b39e9-e9d8-4c51-a76a-ad150bb127f1 |
Comparison | Intervention | NCT00429182 | NCT00429507 | the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00429182', 'Intervention': ['INTERVENTION 1: ', ' High-dose Chemotherapy', ' Carboplatin + Cyclophosphamide + Thiotepa', ' Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.', ' Thiotepa : 120 mg/m^2 by vein days -6... | {'Clinical Trial ID': 'NCT00429507', 'Intervention': ['INTERVENTION 1: ', ' Samarium 153-EDTMP + Stem Cell Transplant', ' Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant D... | 67a628d7-d883-44b9-b351-901f20fd5d0a |
Single | Adverse Events | NCT00448591 | Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial. | Contradiction | [
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00448591', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' Participants received bevacizumab 15 mg/kg iv on Day 1 of each 3 week cycle, or 10 mg/kg iv on Day 1 of each 2 week cycle (weekly equivalent dose of 5 mg/kg/week) along with Taxane-based chemotherapy as prescribed'], 'Eligibil... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 78c60212-28f7-4306-9f63-549be04687b2 | |
Comparison | Eligibility | NCT01593020 | NCT00834678 | Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial. | Contradiction | [
13,
18
] | [
23
] | {'Clinical Trial ID': 'NCT01593020', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel Weekly for 12 Doses Followed by FAC/FEC', ' Patients will receive Paclitaxel 80 mg/m2 IVPB over 1 hour weekly for 12 doses followed by FAC/FEC.', 'INTERVENTION 2: ', ' Eribulin on Days 1 and 8 Every 3 Weeks for 4 Cycles (21 Day Cy... | {'Clinical Trial ID': 'NCT00834678', 'Intervention': ['INTERVENTION 1: ', ' Bendamustine and Erlotinib', ' Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Participants in dose level II were administered 1... | a72e1259-50be-48e5-bdf8-296040cbf7ce |
Single | Results | NCT03366428 | 0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT03366428', 'Intervention': ['INTERVENTION 1: ', ' DS-8201a', ' Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Has a pathologically documented unresectable or metast... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19cfd511-8582-4116-8d51-7ec4a6221022 | |
Single | Results | NCT00820170 | According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00820170', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib and Paclitaxel', ' The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly p... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3f012bd3-bb89-414b-9dd9-35cef524a69a | |
Single | Eligibility | NCT02600923 | Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT02600923', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole', ' Participants received palbociclib orally once daily at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle, and letrozole orally at 2.5 mg QD as a continuous daily dosing schedule. Participants ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5eafb3a1-473a-4270-848d-173e5dca9466 | |
Comparison | Intervention | NCT00711529 | NCT02835625 | the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00711529', 'Intervention': ['INTERVENTION 1: ', ' Hypnotherapy', ' Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of sel... | {'Clinical Trial ID': 'NCT02835625', 'Intervention': ['INTERVENTION 1: ', ' Digital Breast Tomosynthesis', ' Digital Breast Tomosynthesis + Synthetic Mammography (DBT)', ' The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for furth... | ed956644-5228-4915-b706-1cedb0462577 |
Single | Adverse Events | NCT00281697 | the primary trial does not record any cardiac related adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00281697', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy + Bevacizumab', ' Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks dependin... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 02158762-9490-46a1-b494-0589885fd4ce | |
Comparison | Adverse Events | NCT00217672 | NCT00110084 | the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial. | Entailment | [
0,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT00217672', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Bevacizumab', ' docetaxel: 75 mg/m2 IV q3 weeks. Bevacizumab: 15mg/kg IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.'], 'Eligibility': [... | {'Clinical Trial ID': 'NCT00110084', 'Intervention': ['INTERVENTION 1: ', ' Nab-paclitaxel/Gemcitabine', ' Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle'], 'Eligibility': ['DISEASE CHA... | c0a8e1a0-cbe6-4240-b578-59afa4d6cf23 |
Comparison | Intervention | NCT00686127 | NCT01129622 | dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00686127', 'Intervention': ['INTERVENTION 1: ', ' Lidocaine Patch', ' Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day.', 'INTERVENTION 2: ', ' Placebo Patch', ' Placebo patch: 1 patch was applied topical... | {'Clinical Trial ID': 'NCT01129622', 'Intervention': ['INTERVENTION 1: ', ' Letrozole, Breast Enhancement, Safety', ' Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment). Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI.'], 'Eligibili... | 7ec286e9-f519-41da-848d-a0bc5a50c0ee |
Comparison | Intervention | NCT00256698 | NCT03573804 | the primary trial and the secondary trial use completely different drugs and techniques for their interventions, however they both require trained Radiologists on site for evaluation. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00256698', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Anastrozole', ' Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg', 'INTERVENTION 2: ', ' Anastrozole', 'Anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Signed informed consent, postmenopausal females, hi... | {'Clinical Trial ID': 'NCT03573804', 'Intervention': ['INTERVENTION 1: ', ' Prone to Supine MRI Evaluated by Radiologist A', ' Radiologist A, number of participants successfully segmented', 'INTERVENTION 2: ', ' Prone to Supine MRI Evaluated by Radiologist B', ' Radiologist B, number of participants successfully se... | d0af59a9-04ae-4922-97eb-dc29f5bc44e3 |
Single | Intervention | NCT00509587 | Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00509587', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Pazopanib Hydrochloride)', ' Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.', ' pazopanib hydrochloride: Given orally', ' phar... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5d4cbb15-ea50-4394-b1b9-ab4553b5b275 | |
Single | Adverse Events | NCT00777049 | All 4 of the CHF cases in the primary trial, were in cohort 1. | Contradiction | [
0,
6,
14,
20
] | [] | {'Clinical Trial ID': 'NCT00777049', 'Intervention': ['INTERVENTION 1: ', ' ER+ and/or PgR+ (Arm I)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg', 'INTERVENTION 2: ', ' ER- and PgR- (Arm II)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg'], 'Eligibility': ['Inclusion Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8 | |
Comparison | Adverse Events | NCT02366130 | NCT01262027 | the primary trial and the secondary trial have entirely different adverse event profiles. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02366130', 'Intervention': ['INTERVENTION 1: ', ' Ra-223 Dichloride + Denosumab', ' Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.', ... | {'Clinical Trial ID': 'NCT01262027', 'Intervention': ['INTERVENTION 1: ', ' Dovitinib', ' Dovitinib 500 mg single oral dose for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Patients have histological confirmati... | 78a5162d-140a-4631-b776-5c284446b5ec |
Comparison | Adverse Events | NCT01026142 | NCT00846027 | There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial. | Entailment | [
0,
7,
12,
19
] | [
0,
4
] | {'Clinical Trial ID': 'NCT01026142', 'Intervention': ['INTERVENTION 1: ', ' A: Capecitabine + Trastuzumab', ' Capecitabine [Xeloda]: 1250 mg/m2 po twice daily for 14 days every 3 weeks. Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.', 'INTERVENTION 2: ', ' B: Capecitabine + Trastuzumab +... | {'Clinical Trial ID': 'NCT00846027', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Paclitaxel + Gemcitabine', ' Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptabl... | 633ef768-9e9b-4336-9142-8d4ce7ee2342 |
Single | Intervention | NCT00826267 | Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21 | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00826267', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', 'INTERVENTION 2: ', ' Lapatinib 1500 mg', ' Patients... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7c5b29bc-ac37-48bb-abb1-a102174f79ef | |
Single | Results | NCT00708214 | All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00708214', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg With Letrozole', ' Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression.', 'INTERVENTION 2: ', ' Afatinib 40 mg With Letrozo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b8881e2e-ca25-4c1b-bbd2-281ebdb7514a |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.